NCT03692897

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 1,708 (actual)
• Sponsor: Target PharmaSolutions, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Conditions

• Hepatitis B
• Hepatitis
• Liver Diseases

Interventions

Type	Name	Description
OTHER	All approved therapies for the treatment of Chronic Hepatitis B (CHB)	All approved therapies for the treatment of Chronic Hepatitis B (CHB).

Timeline

• Start date: 2018-10-11
• Primary completion: 2025-09-10
• Completion: 2025-09-10
• First posted: 2018-10-02
• Last updated: 2025-09-17

Locations

31 sites across 2 countries: United States, Canada